View Item 

Show simple item record

Functional factor VIII made with von Willebrand factor at high levels in transgenic milk

dc.contributor.authorPipe, Steven W.en_US
dc.contributor.authorMiao, H. Z.en_US
dc.contributor.authorButler, S. P.en_US
dc.contributor.authorCalcaterra, J.en_US
dc.contributor.authorVelander, W. H.en_US
dc.date.accessioned2011-12-05T18:32:11Z
dc.date.available2013-01-02T16:32:38Zen_US
dc.date.issued2011-11en_US
dc.identifier.citationPipe, S. W. ; Miao, H. ; Butler, S. P. ; Calcaterra, J. ; Velander, W. H. (2011). "Functional factor VIII made with von Willebrand factor at high levels in transgenic milk." Journal of Thrombosis and Haemostasis 9(11). <http://hdl.handle.net/2027.42/88017>en_US
dc.identifier.issn1538-7933en_US
dc.identifier.issn1538-7836en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/88017
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherFactor VIIIen_US
dc.subject.otherHemophiliaen_US
dc.subject.otherMammary Glanden_US
dc.subject.otherModified B Domainen_US
dc.subject.otherRecombinant Proteinen_US
dc.subject.otherTransgenic Animalen_US
dc.subject.otherVon Willebrand Factoren_US
dc.titleFunctional factor VIII made with von Willebrand factor at high levels in transgenic milken_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Pediatrics, University of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationotherDepartment of Biochemistry, Virginia Polytechnic Institute and State University, Blacksburg, VAen_US
dc.contributor.affiliationotherDepartment of Chemical & Biomolecular Engineering, University of Nebraska, Lincoln, NE, USAen_US
dc.identifier.pmid21920013en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/88017/1/j.1538-7836.2011.04505.x.pdf
dc.identifier.doi10.1111/j.1538-7836.2011.04505.xen_US
dc.identifier.sourceJournal of Thrombosis and Haemostasisen_US
dc.identifier.citedreferenceKasper CK, Mannucci PM, Bulyzhenkov V, Brettler DB, Chuansumrit A, Heijnen L, Isarankura P, Kernoff PB, Peake I, Rickard KA, Schulman S, Smit Sibinga CT. Haemophilia in the 1990s: report of a joint meeting of the World Health Organization and World Federation of Hemophilia. Vox Sang 1991; 61: 221 – 4.en_US
dc.identifier.citedreferenceRosendaal FR, Briet E. The increasing prevalence of haemophilia. Thromb Haemost 1990; 63: 145.en_US
dc.identifier.citedreferenceHoyer LW. Hemophilia A. N Engl J Med 1994; 330: 38 – 47.en_US
dc.identifier.citedreferenceWood WI, Capon DJ, Simonsen CC, Eaton DL, Gitschier J, Keyt B, Seeburg PH, Smith DH, Hollingshead P, Wion KL, Delwart E, Tuddenham EGD, Vehar GA, Lawn RM. Expression of active human factor VIII from recombinant DNA clones. Nature (London) 1984; 312: 330 – 7.en_US
dc.identifier.citedreferenceVehar GA, Keyt B, Eaton D, Rodriguez H, O’Brien DP, Rotblat F, Oppermann H, Keck R, Wood WI, Harkins RN, Tuddenham EGD, Lawn RM, Capon DJ. Structure of human factor VIII. Nature (London) 1984; 312: 337 – 42.en_US
dc.identifier.citedreferenceToole JJ, Knopf JL, Wozney JM, Sultzman LA, Buecker JL, Pittman DD, Kaufman RJ, Brown E, Shoemaker C, Orr EC, Amphlett GW, Foster WB, Coe ML, Knutson GJ, Fass DN, Hewick RM. Molecular cloning of a cDNA encoding human antihemophilic factor. Nature (London) 1984; 312: 342 – 7.en_US
dc.identifier.citedreferenceJankowski MA, Patel H, Rouse JC, Marzilli LA, Weston SB, Sharpe PJ. Defining ‘full‐length’ recombinant factor VIII: a comparative structural analysis. Haemophilia 2007; 13: 30 – 7.en_US
dc.identifier.citedreferencePipe SW, High KA, Ohashi K, Ural AU, Lillicrap D. Progress in the molecular biology of inherited bleeding disorders. Haemophilia 2008; 14 ( Suppl. 3 ): 130 – 7.en_US
dc.identifier.citedreferencePipe SW, Saint‐Remy J‐M, Walsh CE. New high‐technology products for the treatment of haemophilia. Haemophilia 2004; 10: 55 – 63.en_US
dc.identifier.citedreferenceLynch CM, Israel DI, Kaufman RJ, Miller AD. Sequences in the coding region of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production. Hum Gene Ther 1993; 4: 259 – 72.en_US
dc.identifier.citedreferenceKoeberl DD, Halbert CL, Krumm A, Miller AD. Sequences within the coding regions of clotting factor VIII and CFTR block transcriptional elongation. Hum Gene Ther 1995; 6: 469 – 79.en_US
dc.identifier.citedreferenceHoeben RC, Fallaux FJ, Cramer SJ, van den Wollenberg DJM, van Ormondt H, Brieet E, van der Eb AJ. Expression of the blood‐clotting factor‐VIII cDNA is repressed by a transcriptional silencer located in its coding region. Blood 1995; 85: 2447 – 54.en_US
dc.identifier.citedreferenceKaufman RJ, Wasley LC, Dorner AJ. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem 1988; 263: 6352 – 62.en_US
dc.identifier.citedreferenceMiao HZ, Sirachainan N, Palmer L, Kucab P, Cunningham MA, Kaufman RJ, Pipe SW. Bioengineering of coagulation factor VIII for improved secretion. Blood 2004; 103: 3412 – 19.en_US
dc.identifier.citedreferencePittman DD, Millenson M, Marquette K, Bauer K, Kaufman RJ. A2 domain of human recombinant‐derived factor VIII is required for procoagulant activity but not for thrombin cleavage. Blood 1992; 79: 389 – 97.en_US
dc.identifier.citedreferenceKaufman RJ, Wasley LC, Davies MV, Wise RJ, Israel DI, Dorner AJ. Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells. Mol Cell Biol 1989; 9: 1233 – 42.en_US
dc.identifier.citedreferenceChen C‐M, Wang C‐H, Wu S‐C, Lin C‐C, Lin S‐H, Cheng WTK. Temporal and spatial expression of biologically active human factor VIII in the milk of transgenic mice driven by mammary‐specific bovine lactalbumin regulation sequences. Transgenic Res 2002; 11: 257 – 68.en_US
dc.identifier.citedreferenceChrenek P, Vasicek D, Makarevich AV, Jurcik R, Suvegova K, Parkanyi V, Bauer M, Rafay J, Batorova A, Paleyanda RK. Increased transgene integration efficiency upon microinjection of DNA into both pronuclei of rabbit embryos. Transgenic Res 2005; 14: 417 – 28.en_US
dc.identifier.citedreferenceCherenek P, Ryban L, Vetr H, Makarevich AV, Uhrin P, Paleyanda RK, Binder BR. Expression of recombinant human factor viii in milk of several generations of transgenic rabbits. Transgenic Res 2007; 16: 353 – 61.en_US
dc.identifier.citedreferenceNiemann H, Halter R, Carnwath JW, Hermann D, Lemme E, Paul D. Expression of human blood clotting factor VIII in the mammary gland of transgenic sheep. Transgenic Res 1999; 8: 237 – 47.en_US
dc.identifier.citedreferencePaleyanda RK, Velander WH, Lee TK, Scandella DH, Gwazdauskas FC, Knight JW, Drohan WN, Lubon H. Transgenic pig produce functional human factor VIII in milk. Nat Biotechnol 1997; 15: 971 – 5.en_US
dc.identifier.citedreferenceChauhan MS, Nadir S, Bailey TL, Pryor AW, Butler SP, Notter DR, Velander WH, Gwazdauskas FC. Bovine follicular dynamics, oocyte recovery, and development of oocytes microinjected with a green fluorescent protein construct. J Dairy Sci 1999; 82: 918 – 26.en_US
dc.identifier.citedreferenceArchibald AL, McClenaghan M, Hornsey V, Simons JP, Clark AJ. High‐level expression of biologically active human alpha 1‐antitrypsin in the milk of transgenic mice. Proc Natl Acad Sci USA 1990; 87: 5178 – 82.en_US
dc.identifier.citedreferenceVelander WH, Page RL, Morcol T, Russell CG, Canseco R, Young JM, Drohan WN, Gwazdauskas FC, Wilkins TD, Johnson JL. Production of biologically active human protein C in the milk of transgenic mice. Ann N Y Acad Sci 1992; 665: 391 – 403.en_US
dc.identifier.citedreferenceMichnick DA, Pittman DD, Wise RJ, Kaufman RJ. Identification of individual tyrosine sulfation sites within factor VIII required for optimal activity and efficient thrombin cleavage. J Biol Chem 1994; 269: 20095 – 102.en_US
dc.identifier.citedreferenceLollar P, Fay PJ, Fass DN. Factor VIII and factor VIIIa. Methods Enzymol 1993; 222: 128 – 43.en_US
dc.identifier.citedreferenceJacquemin MG, Desqueper BG, Benhida A, Vander Elst L, Hoylaerts MF, Bakkus M, Thielemans K, Arnout J, Peerlinck K, Gilles JGG, Vermylen J, Saint‐Remy J‐MR. Mechanism and kinetics of factor viii inactivation: study with an igg4 monoclonal antibody derived from a hemophilia a patient with inhibitor. Blood 1998; 92: 496 – 506.en_US
dc.identifier.citedreferenceBi L, Sarkar R, Naas T, Lawler AM, Pain J, Shumaker SL, Bedian V, Kazazian HH Jr. Further characterization of factor VIII‐deficient mice created by gene targeting: RNA and protein studies. Blood 1996; 88: 3446 – 50.en_US
dc.identifier.citedreferenceClark AJ, Cowper A, Wallac R, Wright G, Simons JP. Rescuing transgene expression by co‐integration. J Biotechnol 1992; 10: 1450 – 4.en_US
dc.identifier.citedreferenceYull F, Binas B, Harold G, Wallace R, Clark AJ. Transgene rescue in the mammary gland is associated with transcription but does not require translation of BLG transgenes. Transgenic Res 1997; 6: 11 – 17.en_US
dc.identifier.citedreferenceAlpan O, Velander WH, van Cott KE, Butler SP, High KA, Sabatino D. Overcoming the immunological barriers to curing haemophilia. In: Studies TSIfB, ed. 6th Gene Therapy Workshop. La Jolla, CA: The Salk Institute for Biological Studies, 2002: 3885 – 91.en_US
dc.identifier.citedreferenceMannucci PM, Bonomi AB. The future of hemophilia treatment. Haematologica/J Hematol 2004; 89: 774 – 6.en_US
dc.identifier.citedreferenceKorycka‐Dahl M, Dumas BR, Chene N, Martal J. Plasmin activity in milk. J Dairy Sci 1983; 66: 704 – 11.en_US
dc.identifier.citedreferenceClark AJ, Bessos H, Bishop JO, Brown P, Lathe HR, McClenaghan M, Prowse C, Simons JP, Whitelaw CBA, Wilmut I. Expression of human anti‐hemophilic factor mix in the milk of transgenic sheep. J Biotechnol 1989; 7: 487 – 92.en_US
dc.identifier.citedreferenceWeiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand’s disease. J Clin Invest 1977; 60: 390 – 404.en_US
dc.identifier.citedreferenceLeyte A, van Schijndel HB, Niehrs C, Huttner WB, Verbeet MP, Mertens K, van Mourik JA. Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J Biol Chem 1991; 266: 740 – 6.en_US
dc.identifier.citedreferencePlatokouki H, Pergantou H, Komitopoulou A, Xafaki P. First attempt at immune tolerance induction with factor VIII/von Willebrand factor concentrates in hemophilia A children with high‐titer inhibitors. J Coagulation Disord 2010; 2: 35 – 40.en_US
dc.identifier.citedreferenceEchelard Y, Ziomek CA, Meade HM. Production of recombinant therapeutic proteins in the milk of transgenic animals. BioPharm Int. 2006; 19: 36 – 40, 2, 4, 6.en_US
dc.identifier.citedreferenceGil GC, Velander WH, van Cott KE. Analysis of the N‐glycans of recombinant human factor IX purified from transgenic pig milk. Glycobiology 2008; 18: 526 – 39.en_US
dc.identifier.citedreferenceJoziasse DH, Lee RT, Lee YC, Biessen EAL, Schiphorst WECM, Koeleman CAM, van den Eijnden DH. Alpha 3‐galactosylated glycoproteins can bind to the hepatic asialoglycoprotein receptor. Eur J Biochem 2000; 267: 6501 – 8.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1538-7836.2011.04505.x.pdf
Size:
539.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.